Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Eugl J Med. 2015;373:23–4.

Google Scholar 

Weber JS, Gibney G, Sullivan RJ, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (Checkmate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016;17:943–55.

CAS  PubMed  PubMed Central  Google Scholar 

Soularue E, Lepage P, Colombel JF, et al. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. 2018;67:2056–67.

CAS  PubMed  Google Scholar 

Dougan M, Wang Y, Rubin-Tapia A, et al. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology. 2021;160:1284–93.

Google Scholar 

Venditti O, De Lisi D, Caricato M, et al. Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis. BMC Cancer. 2015;15:87.

PubMed  PubMed Central  Google Scholar 

Suwaidan AA, Richards CJ, Boyle K, et al. Severe inflammatory ileitis resulting in ileal perforation in association with combination immune checkpoint blockade for metastatic malignant melanoma. BMJ Case Rep. 2018. https://doi.org/10.1136/bcr-2018-224913.

Article  PubMed  Google Scholar 

Smith SCL, Zardo D, Cannatelli R, et al. Endoscopic findings of checkpoint inhibitor-induced ileitis with use of the latest advanced endoscopic optical diagnosis: near-focus narrow-band imaging. VideoGIE. 2019;4:133–5.

PubMed  PubMed Central  Google Scholar 

Otagiri S, Katsurada T, Yamanashi K, et al. Immune checkpoint inhibitor-induced enteritis assessed using capsule endoscopy. JGH Open. 2020;4:1231–2.

PubMed  PubMed Central  Google Scholar 

Wang DY, Ye F, Zhao S, et al. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology. 2017. https://doi.org/10.1080/2162402X.2017.1344805.

Article  PubMed  PubMed Central  Google Scholar 

Tandon P, Bourassa-Blanchette S, Bishay K, et al. The risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis. J Immunother. 2018;41:101–8.

PubMed  Google Scholar 

Magahis PT, Corso T, Livingstone P, et al. Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors. J Immunother Cancer. 2024;12:e009051.

PubMed  PubMed Central  Google Scholar 

Jeay M, Carbonnel F, Robert C, et al. Chronic gastrointestinal immune-related adverse events in patients exposed to immune checkpoint inhibitors. Clin Res Hepatol Gastroenterol. 2024;48:102311.

CAS  PubMed  Google Scholar 

Lo YC, Price C, Blenman K, et al. Checkpoint inhibitor colitis shows drug-specific differences in immune cell reaction that overlap with inflammatory bowel disease and predict response to colitis therapy. Am J Clin Pathol. 2021;156:214–28.

CAS  PubMed  Google Scholar 

Hone Lopez S, Kats-Ugurlu G, Renken RJ, et al. Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis. Virchows Arch. 2021;479:1119–29.

PubMed  PubMed Central  Google Scholar 

Takahashi Y, Nagaya T, Iwaya Y, et al. CD8+ Lymphocyte infiltration is a specific feature of colitis induced by immune checkpoint inhibitors. Dig Dis Sci. 2023;68:451–9.

CAS  PubMed  Google Scholar 

Wang Y, Abu-Sbeih H, Mao E, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis. 2018;24:1695–705.

PubMed  Google Scholar 

Hahnloser D, Pemberton JH, Wolff BG, et al. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br J Surg. 2007;94:333–40.

CAS  PubMed  Google Scholar